Loading...

OncoSec Medical

DB:ONM1
Snowflake Description

Flawless balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ONM1
DB
$36M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

OncoSec Medical Incorporated, a biotechnology company, focuses on the development of cytokine-based intratumoral immunotherapies to stimulate the body’s immune system to target and attack cancer. The last earnings update was 46 days ago. More info.


Add to Portfolio Compare Print
  • OncoSec Medical has significant price volatility in the past 3 months.
ONM1 Share Price and Events
7 Day Returns
-3.9%
DB:ONM1
-2.7%
DE Biotechs
1.5%
DE Market
1 Year Returns
-56.9%
DB:ONM1
-10.6%
DE Biotechs
-6.2%
DE Market
ONM1 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
OncoSec Medical (ONM1) -3.9% 16.4% -10.4% -56.9% -70.3% -
DE Biotechs -2.7% 3.8% -8.5% -10.6% 47.4% 10.3%
DE Market 1.5% 6% 8.5% -6.2% 10.7% 15.3%
1 Year Return vs Industry and Market
  • ONM1 underperformed the Biotechs industry which returned -10.6% over the past year.
  • ONM1 underperformed the Market in Germany which returned -6.2% over the past year.
Price Volatility
ONM1
Industry
5yr Volatility vs Market
Related Companies

Value

 Is OncoSec Medical undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for OncoSec Medical. This is due to cash flow or dividend data being unavailable. The share price is €0.5296.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for OncoSec Medical's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are OncoSec Medical's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:ONM1 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-01-31) in USD $-0.69
NasdaqCM:ONCS Share Price ** NasdaqCM (2019-04-23) in USD $0.59
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.6x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of OncoSec Medical.

DB:ONM1 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:ONCS Share Price ÷ EPS (both in USD)

= 0.59 ÷ -0.69

-0.85x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • OncoSec Medical is loss making, we can't compare its value to the Europe Biotechs industry average.
  • OncoSec Medical is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does OncoSec Medical's expected growth come at a high price?
Raw Data
DB:ONM1 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.85x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
-8.9%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for OncoSec Medical, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on OncoSec Medical's assets?
Raw Data
DB:ONM1 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-01-31) in USD $0.38
NasdaqCM:ONCS Share Price * NasdaqCM (2019-04-23) in USD $0.59
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:ONM1 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:ONCS Share Price ÷ Book Value per Share (both in USD)

= 0.59 ÷ 0.38

1.54x

* Primary Listing of OncoSec Medical.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • OncoSec Medical is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess OncoSec Medical's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. OncoSec Medical has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is OncoSec Medical expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-8.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is OncoSec Medical expected to grow at an attractive rate?
  • Unable to compare OncoSec Medical's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare OncoSec Medical's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Unable to compare OncoSec Medical's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:ONM1 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:ONM1 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts -8.9%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:ONM1 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:ONM1 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-07-31 0 -42 1
2019-07-31 0 -35 2
DB:ONM1 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-01-31 -25 -38
2018-10-31 -25 -41
2018-07-31 -23 -39
2018-04-30 -22 -33
2018-01-31 -20 -27
2017-10-31 -18 -22
2017-07-31 -17 -21
2017-04-30 -17 -22
2017-01-31 -17 -24
2016-10-31 -18 -25
2016-07-31 -18 -27
2016-04-30 -19 -27

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • OncoSec Medical is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Unable to determine if OncoSec Medical is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:ONM1 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from OncoSec Medical Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:ONM1 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-07-31 -0.65 -0.65 -0.65 1.00
2019-07-31 -0.56 -0.56 -0.56 1.00
DB:ONM1 Past Financials Data
Date (Data in USD Millions) EPS *
2019-01-31 -0.69
2018-10-31 -0.84
2018-07-31 -0.98
2018-04-30 -1.01
2018-01-31 -1.09
2017-10-31 -1.03
2017-07-31 -1.06
2017-04-30 -1.14
2017-01-31 -1.30
2016-10-31 -1.45
2016-07-31 -1.63
2016-04-30 -1.75

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if OncoSec Medical will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess OncoSec Medical's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
OncoSec Medical has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has OncoSec Medical performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare OncoSec Medical's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • OncoSec Medical does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare OncoSec Medical's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare OncoSec Medical's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
OncoSec Medical's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from OncoSec Medical Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:ONM1 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-01-31 -38.39 17.38 20.09
2018-10-31 -40.81 18.94 18.74
2018-07-31 -39.14 18.69 17.42
2018-04-30 -32.60 16.63 12.58
2018-01-31 -27.10 12.38 12.38
2017-10-31 -21.75 9.63 12.27
2017-07-31 -21.45 9.67 11.95
2017-04-30 -22.11 10.08 12.23
2017-01-31 -23.80 10.94 12.95
2016-10-31 -25.45 11.32 14.18
2016-07-31 -26.89 12.14 14.74
2016-04-30 -26.90 11.91 14.99
2016-01-31 -26.64 11.09 15.54
2015-10-31 -24.22 9.93 14.29
2015-07-31 -21.24 8.11 13.13
2015-04-30 -18.21 7.05 11.16
2015-01-31 -16.04 7.11 8.92
2014-10-31 -14.02 6.50 7.52
2014-07-31 -12.01 6.15 5.80
2014-04-30 -10.24 5.44 4.73
2014-01-31 -8.15 4.32 3.74
2013-10-31 -7.17 4.30 2.75
2013-07-31 -7.15 3.91 3.16
2013-04-30 -6.97 3.86 3.01
2013-01-31 -6.05 3.75 3.00
2012-10-31 -7.10 3.30 3.03
2012-07-31 -2.36 3.16 2.37
2012-04-30 -4.02 3.00 2.16

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if OncoSec Medical has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if OncoSec Medical has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if OncoSec Medical improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess OncoSec Medical's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
OncoSec Medical has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is OncoSec Medical's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up OncoSec Medical's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • OncoSec Medical is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • OncoSec Medical's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of OncoSec Medical's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • OncoSec Medical has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from OncoSec Medical Company Filings, last reported 2 months ago.

DB:ONM1 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-01-31 24.67 0.00 28.73
2018-10-31 25.20 0.00 28.47
2018-07-31 22.92 0.00 26.98
2018-04-30 32.70 0.00 30.28
2018-01-31 18.03 0.00 17.90
2017-10-31 13.54 0.00 14.66
2017-07-31 10.70 0.00 11.44
2017-04-30 15.96 0.00 16.11
2017-01-31 19.70 0.00 20.54
2016-10-31 23.64 0.00 24.35
2016-07-31 28.05 0.00 28.75
2016-04-30 23.99 0.00 24.02
2016-01-31 28.59 0.00 28.85
2015-10-31 27.22 0.00 26.90
2015-07-31 32.70 0.00 32.04
2015-04-30 25.89 0.00 25.44
2015-01-31 31.21 0.00 30.70
2014-10-31 34.62 0.00 33.99
2014-07-31 38.07 0.00 37.85
2014-04-30 24.52 0.00 24.25
2014-01-31 18.89 0.00 18.45
2013-10-31 15.20 0.00 15.19
2013-07-31 4.74 0.00 4.97
2013-04-30 6.38 0.00 7.33
2013-01-31 8.02 0.00 8.98
2012-10-31 2.69 0.00 3.53
2012-07-31 4.43 0.00 5.14
2012-04-30 5.81 0.00 6.57
  • OncoSec Medical has no debt.
  • OncoSec Medical has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • OncoSec Medical has sufficient cash runway for 1.1 years based on current free cash flow.
  • OncoSec Medical has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 8.2% each year.
X
Financial health checks
We assess OncoSec Medical's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. OncoSec Medical has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is OncoSec Medical's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from OncoSec Medical dividends.
If you bought €2,000 of OncoSec Medical shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate OncoSec Medical's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate OncoSec Medical's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:ONM1 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:ONM1 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2020-07-31
2019-07-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as OncoSec Medical has not reported any payouts.
  • Unable to verify if OncoSec Medical's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of OncoSec Medical's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as OncoSec Medical has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess OncoSec Medical's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can OncoSec Medical afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. OncoSec Medical has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of OncoSec Medical's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Dan O’Connor
COMPENSATION $4,191,583
AGE 54
TENURE AS CEO 1.4 years
CEO Bio

Mr. Daniel J. O’Connor, also known as Dan, J.D. has been the Chief Executive Officer of OncoSec Medical Incorporated since November 7, 2017 and President since May 02, 2018. Mr. O’Connor serves as Director of Seelos Therapeutics, Inc. He served as President and Chief Executive Officer of Advaxis Immunotherapies. Mr. O’Connor has more than 20 years of successful financing and licensing experience. Mr. O’Connor was also instrumental in establishing major partnerships with companies that include Amgen Inc., Merck & Co. and Bristol Myers Squibb. Previously, Mr. O’Connor was Senior Vice President for ImClone Systems where he supported the clinical development, launch and commercialization of ERBITUX®, and the sale of it to Eli Lilly in 2008. Mr. O’Connor served as General Counsel at PharmaNet (inventive Health) and was part of the senior leadership team that grew it from a start-up contract research organization into a leader in clinical research. He has been a Director of OncoSec Medical Incorporated since September 7, 2017. He was commissioned as an officer in the U.S. Marines, attaining the rank of Captain while serving in Saudi Arabia during Operation Desert Shield. Mr. O’Connor serves as Vice Chairman of BioNJ and was a former New Jersey criminal prosecutor. Mr. O’Connor is a 1995 graduate of the Penn State University's Dickinson School of Law in Carlisle, Pennsylvania and serves as an Entrepreneur Trusted Advisor to its Dean. He graduated from the United States Marines Corps Officer Candidate School in 1988.

CEO Compensation
  • Insufficient data for Dan to compare compensation growth.
  • Dan's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the OncoSec Medical management team in years:

1.4
Average Tenure
42
Average Age
  • The average tenure for the OncoSec Medical management team is less than 2 years, this suggests a new team.
Management Team

Avtar Dhillon

TITLE
Co-Founder & Chairman
COMPENSATION
$541K
AGE
56

Dan O’Connor

TITLE
President
COMPENSATION
$4M
AGE
54
TENURE
1.4 yrs

Punit Dhillon

TITLE
Co-Founder & Director
COMPENSATION
$3M
AGE
38
TENURE
8.1 yrs

Sara Bonstein

TITLE
CFO, COO & Company Secretary
COMPENSATION
$919K
AGE
37
TENURE
0.8 yrs

Christopher Twitty

TITLE
Chief Scientific Officer
TENURE
1.3 yrs

Keir Loiacono

TITLE
VP of Legal & Corporate Development and Chief Compliance Officer

Tu Diep

TITLE
Senior VP & Head of Operations
TENURE
4.6 yrs

Kellie Malloy Foerter

TITLE
Chief Clinical Development Officer
TENURE
0.5 yrs

Mai Hope Le

TITLE
Consultant
COMPENSATION
$924K
AGE
42
TENURE
3.3 yrs
Board of Directors Tenure

Average tenure and age of the OncoSec Medical board of directors in years:

7.1
Average Tenure
52.5
Average Age
  • The tenure for the OncoSec Medical board of directors is about average.
Board of Directors

Avtar Dhillon

TITLE
Co-Founder & Chairman
COMPENSATION
$541K
AGE
56
TENURE
8.1 yrs

Dan O’Connor

TITLE
President
COMPENSATION
$4M
AGE
54
TENURE
1.6 yrs

Punit Dhillon

TITLE
Co-Founder & Director
COMPENSATION
$3M
AGE
38
TENURE
8.1 yrs

Jim DeMesa

TITLE
Independent Director
COMPENSATION
$103K
AGE
60
TENURE
8.2 yrs

Greg Mayes

TITLE
Director
COMPENSATION
$155K
AGE
49
TENURE
1.3 yrs

Richard Heller

TITLE
Member of Scientific Advisory Board
TENURE
8.3 yrs

Iacob Mathiesen

TITLE
Member of Scientific Advisory Board
AGE
51
TENURE
8.3 yrs

Axel Hauschild

TITLE
Member of Clinical Advisory Board
TENURE
6.2 yrs

Soldano Ferrone

TITLE
Member of Scientific Advisory Board
TENURE
4.8 yrs

Alain Algazi

TITLE
Member of Clinical Advisory Board
TENURE
0.7 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
26. Nov 18 Buy James DeMesa Individual 07. Nov 18 20. Nov 18 8,500 €0.80 €6,112
07. Nov 18 Buy Daniel O'Connor Individual 07. Nov 18 07. Nov 18 10,000 €0.79 €7,932
X
Management checks
We assess OncoSec Medical's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. OncoSec Medical has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

OncoSec Medical Incorporated, a biotechnology company, focuses on the development of cytokine-based intratumoral immunotherapies to stimulate the body’s immune system to target and attack cancer. Its lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor. The company is also developing ImmunoPulse IL-12 with KEYTRUDA in patients with advanced melanoma that is in the Phase IIb clinical trials (PISCES/KEYNOTE-695) and advanced or metastatic triple negative breast cancer (TNBC), which is in the Phase II clinical trials (OMS-141/KEYNOTE-890); ImmunoPulse IL-12 and KEYTRUDA in patients with advanced or metastatic melanoma that has completed Phase II clinical trials; and ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma, which has completed the Phase II clinical trials. In addition, it undertakes the phase II monotherapy biomarker study in patients with advanced or metastatic TNBC. Further, the company has completed Phase I neoadjuvant clinical trial of ImmunoPulse IL-12 in combination with an anti-PD-1 in surgically resectable melanoma. Additionally, it is developing new DNA-encoded therapeutic candidates and tumor indications. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the PISCES/KEYNOTE-695 and OMS-141/KEYNOTE-890 studies; a collaboration with the GOG Foundation, Inc. to conduct a registration-enabled study of tavokinogene telseplasmid in women with recurrent/persistent cervical cancer; and a collaborative research agreement with Duke University School of Medicine in HER2+ breast cancer. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in Pennington, New Jersey.

Details
Name: OncoSec Medical Incorporated
ONM1
Exchange: DB
Founded: 2008
$32,462,979
64,808,769
Website: http://oncosec.com
Address: OncoSec Medical Incorporated
24 North Main Street,
Pennington,
New Jersey, 08534,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM ONCS Common Stock Nasdaq Capital Market US USD 10. Dec 2008
DB ONM1 Common Stock Deutsche Boerse AG DE EUR 10. Dec 2008
LSE 0KC7 Common Stock London Stock Exchange GB USD 10. Dec 2008
Number of employees
Current staff
Staff numbers
34
OncoSec Medical employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/23 22:08
End of day share price update: 2019/04/23 00:00
Last estimates confirmation: 2019/04/23
Last earnings filing: 2019/03/08
Last earnings reported: 2019/01/31
Last annual earnings reported: 2018/07/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.